
Dr Lopetegui-Lia on Adjuvant Therapy for Early-Stage TNBC With Residual Disease
“[One] area of high unmet need is [how to approcah treatment for] patients with early-stage, high-risk TNBC who receive neoadjuvant chemoimmunotherapy and then have residual disease at the time of surgery.” Nerea Lopetegui-Lia, MD, a breast medical …